Insider Ledger
Pharvaris N.V. (PHVS) insider buying and SEC filings
Pharvaris N.V. · CIK 1830487
Tracked: Forms 3/4/5, 8-K, NT · Limited coverage: files 6-K/20-F, not covered in v1 · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Pharmaceutical Preparations
- State of incorporation
- P7
- Fiscal year end
- Dec 31
- Former names
- Pharvaris, B.V.
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$9.2M
Planned sales (10b5-1)
$15.9M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Sep 21, 2026 | Sale | David W. Nassif (CFO) sold 6,000 shares at about $36.47 ($219K). Holdings down 5% to 114,300 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Sep 23, 2026 |
| Sep 17, 2026 | Sale | Johannes Gerardus Christiaan Petrus Schikan (Director) sold 200,000 shares at $35.00 ($7.0M). Holdings down 63% to 115,167 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Sep 21, 2026 |
| Sep 17, 2026 | Planned (10b5-1) | Robert Glassman (Director) sold 14,493 shares at about $38.56 ($559K), marked as a 10b5-1 plan trade. Holdings down 58% to 10,500 shares. | SEC filing Filed Sep 21, 2026 |
| Sep 17, 2026 | Sale | Anne Lesage (Chief Early Development) sold 20,000 shares indirectly at about $38.27 ($765K). Indirect holdings down 21% to 73,969 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Sep 21, 2026 |
| Sep 15, 2026 | Planned (10b5-1) | Robert Glassman (Director) sold 8,667 shares at about $38.27 ($332K), marked as a 10b5-1 plan trade. Holdings down 45% to 10,500 shares. | SEC filing Filed Sep 17, 2026 |
| Sep 14–15, 2026 | Planned (10b5-1) | Wim Souverijns (Chief Commercial Officer) sold 26,090 shares between Sep 14 and Sep 15 at about $39.24 ($1.0M), marked as a 10b5-1 plan trade. Holdings down 40% to 39,021 shares. | SEC filing Filed Sep 16, 2026 |
| Sep 14, 2026 | Planned (10b5-1) | Berndt Modig (CEO and Director) sold 2,291 shares at about $39.40 ($90K), marked as a 10b5-1 plan trade. Holdings down 2% to 128,334 shares. | SEC filing Filed Sep 15, 2026 |
| Sep 11, 2026 | Planned (10b5-1) | Peng Lu (President / COO) sold 15,000 shares at about $40.13 ($602K), marked as a 10b5-1 plan trade. Holdings down 19% to 65,179 shares. | SEC filing Filed Sep 15, 2026 |
| Sep 10, 2026 | Planned (10b5-1) | Anne Lesage (Chief Early Development) sold 30,000 shares at about $38.30 ($1.1M), marked as a 10b5-1 plan trade. Holdings down 35% to 56,450 shares. | SEC filing Filed Sep 14, 2026 |
| Sep 9, 2026 | Planned (10b5-1) | Robert Glassman (Director) sold 8,000 shares at about $37.55 ($300K), marked as a 10b5-1 plan trade. Holdings down 43% to 10,500 shares. | SEC filing Filed Sep 11, 2026 |
| Sep 8, 2026 | Planned (10b5-1) | Peng Lu (President / COO) sold 15,000 shares at about $40.68 ($610K), marked as a 10b5-1 plan trade. Holdings down 19% to 65,179 shares. | SEC filing Filed Sep 9, 2026 |
| Aug 14, 2026 | Planned (10b5-1) | Berndt Modig (CEO and Director) sold 2,292 shares at $34.77 ($80K), marked as a 10b5-1 plan trade. Holdings down 2% to 130,625 shares. | SEC filing Filed Aug 18, 2026 |
| Jul 13, 2026 | Planned (10b5-1) | Berndt Modig (CEO and Director) sold 2,292 shares at about $34.97 ($80K), marked as a 10b5-1 plan trade. Holdings down 2% to 132,917 shares. | SEC filing Filed Jul 15, 2026 |
| Jun 29–30, 2026 | Planned (10b5-1) | Johannes Gerardus Christiaan Petrus Schikan (Director) sold 37,600 shares between Jun 29 and Jun 30 at about $35.41 ($1.3M), marked as a 10b5-1 plan trade. Holdings down 11% to 315,167 shares. | SEC filing Filed Jul 1, 2026 |
| Jun 29–30, 2026 | Planned (10b5-1) | Anne Lesage (Chief Early Development) sold 76,172 shares directly and indirectly between Jun 29 and Jun 30 at about $35.39 ($2.7M), marked as a 10b5-1 plan trade. Direct holdings down 40% to 58,750 shares. | SEC filing Filed Jul 1, 2026 |
| Jun 29, 2026 | Planned (10b5-1) | Johannes Gerardus Christiaan Petrus Schikan (Director) sold 2,400 shares at about $35.10 ($84K), marked as a 10b5-1 plan trade. Holdings down 1% to 352,767 shares. | SEC filing Filed Jun 29, 2026 |
| Jun 25, 2026 | Planned (10b5-1) | Anne Lesage (Chief Early Development) sold 4,600 shares directly and indirectly at about $35.12 ($162K), marked as a 10b5-1 plan trade. Direct holdings down 4% to 56,450 shares. | SEC filing Filed Jun 29, 2026 |
| Jun 25–26, 2026 | Planned (10b5-1) | Peng Lu (Chief Medical Officer) sold 29,700 shares between Jun 25 and Jun 26 at about $34.30 ($1.0M), marked as a 10b5-1 plan trade. Holdings down 31% to 65,631 shares. | SEC filing Filed Jun 29, 2026 |
| Jun 18, 2026 | Planned (10b5-1) | Peng Lu (Chief Medical Officer) sold 300 shares at $34.00 ($10K), marked as a 10b5-1 plan trade. Holdings down <1% to 65,631 shares. | SEC filing Filed Jun 23, 2026 |
| Jun 15, 2026 | Planned (10b5-1) | Berndt Modig (CEO and Director) sold 2,291 shares at about $31.07 ($71K), marked as a 10b5-1 plan trade. Holdings down 2% to 135,209 shares. | SEC filing Filed Jun 17, 2026 |
| Jun 4, 2026 | Sale | Anna Nijdam (Principal Accounting Officer) sold 2,670 shares at about $30.87 ($82K). Holdings down 5% to 46,275 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 8, 2026 |
| May 21, 2026 | Sale | Viviane Monges (Director) sold 9,667 shares at about $30.29 ($293K). Holdings down 64% to 5,500 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 26, 2026 |
| May 21, 2026 | Sale | David W. Nassif (CFO) sold 10,000 shares at about $30.31 ($303K). Holdings down 8% to 120,300 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 26, 2026 |
| May 20, 2026 | Planned (10b5-1) | Elisabeth Bjork (Director) sold 10,000 shares at about $29.32 ($293K), marked as a 10b5-1 plan trade. Holdings down 40% to 15,167 shares. | SEC filing Filed May 22, 2026 |
| May 18, 2026 | Planned (10b5-1) | Berndt Modig (CEO and Director) sold 2,292 shares at about $29.22 ($67K), marked as a 10b5-1 plan trade. Holdings down 2% to 137,500 shares. | SEC filing Filed May 20, 2026 |
| May 15, 2026 | Sale | Robert Glassman (Director) sold 10,000 shares at about $29.83 ($298K). Holdings down 49% to 10,500 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 19, 2026 |
| May 15, 2026 | Sale | Stefan Andreas Abele (Chief Technical Ops Officer) sold 8,748 shares at $29.82 ($261K). Holdings down 20% to 35,194 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 19, 2026 |
| May 15, 2026 | Planned (10b5-1) | Wim Souverijns (Chief Commercial Officer) sold 10,000 shares at about $29.92 ($299K), marked as a 10b5-1 plan trade. Holdings down 18% to 45,111 shares. | SEC filing Filed May 19, 2026 |
| May 1, 2026 | Planned (10b5-1) | Peng Lu (Chief Medical Officer) sold 14,166 shares at about $30.17 ($427K), marked as a 10b5-1 plan trade. Holdings down 18% to 66,083 shares. | SEC filing Filed May 5, 2026 |
| Apr 29–30, 2026 | Planned (10b5-1) | Johannes Gerardus Christiaan Petrus Schikan (Director) sold 32,900 shares between Apr 29 and Apr 30 at about $30.29 ($996K), marked as a 10b5-1 plan trade. Holdings down 8% to 355,167 shares. | SEC filing Filed May 1, 2026 |
| Apr 29–30, 2026 | Planned (10b5-1) | Anne Lesage (Chief Early Development) sold 48,300 shares directly and indirectly between Apr 29 and Apr 30 at about $30.23 ($1.5M), marked as a 10b5-1 plan trade. Direct holdings down 31% to 56,450 shares. | SEC filing Filed May 1, 2026 |
| Apr 29–30, 2026 | Planned (10b5-1) | Peng Lu (Chief Medical Officer) sold 18,733 shares between Apr 29 and Apr 30 at about $30.20 ($566K), marked as a 10b5-1 plan trade. Holdings down 22% to 66,083 shares. | SEC filing Filed May 1, 2026 |
| Apr 22–23, 2026 | Planned (10b5-1) | Johannes Gerardus Christiaan Petrus Schikan (Director) sold 7,100 shares between Apr 22 and Apr 23 at about $30.05 ($213K), marked as a 10b5-1 plan trade. Holdings down 2% to 388,067 shares. | SEC filing Filed Apr 24, 2026 |
| Apr 22–23, 2026 | Planned (10b5-1) | Anne Lesage (Chief Early Development) sold 14,700 shares directly and indirectly between Apr 22 and Apr 23 at about $30.05 ($442K), marked as a 10b5-1 plan trade. Direct holdings down 12% to 56,450 shares. | SEC filing Filed Apr 24, 2026 |
| Apr 22–23, 2026 | Planned (10b5-1) | Peng Lu (Chief Medical Officer) sold 7,101 shares between Apr 22 and Apr 23 at about $30.05 ($213K), marked as a 10b5-1 plan trade. Holdings down 10% to 66,083 shares. | SEC filing Filed Apr 24, 2026 |
| Apr 16, 2026 | Planned (10b5-1) | Berndt Modig (CEO and Director) sold 2,292 shares at about $28.60 ($66K), marked as a 10b5-1 plan trade. Holdings down 2% to 139,792 shares. | SEC filing Filed Apr 20, 2026 |
| Apr 9, 2026 | Planned (10b5-1) | Berndt Modig (CEO and Director) sold 23,333 shares at about $27.75 ($647K), marked as a 10b5-1 plan trade. Holdings down 14% to 142,084 shares. | SEC filing Filed Apr 10, 2026 |
43 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow PHVS in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.